🇺🇸 FDA
Patent

US 10426797

Compositions and methods for treating cancer with anti-CD33 immunotherapy

granted A61KA61K2039/505A61K2239/25

Quick answer

US patent 10426797 (Compositions and methods for treating cancer with anti-CD33 immunotherapy) held by United State of America, As Represented by the Secretary, Dept. of Health and Human Services expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United State of America, As Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K2239/25, A61K2239/38, A61K39/39558